Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma-Reference-Cited by-同舟云学术

Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma

Published:2019-01-16 Issue:6 Volume:42 Page:769-784
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Carlsson Mats^ORCID,Braddock Martin,Li Yuling,Wang Jihong,Xu Weichen,White Nicholas,Megally Ayman,Hunter Gillian,Colice Gene

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

http://link.springer.com/article/10.1007/s40264-018-00788-w/fulltext.html

Reference57 articles.

1. May RD, Monk PD, Cohen ES, Manuel D, Dempsey F, Davis NH, et al. Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma. Br J Pharmacol. 2012;166(1):177–93.

2. Popovic B, Breed J, Rees DG, Gardender MJ, Vinall LMK, Kemp B, et al. Structural characterisation reveals mechanism of IL-13 neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol. 2017;429:208–19.

3. Corren J. Role of interleukin-13 in asthma. Curr Allergy Asthma Rep. 2013;13(5):415–20.

4. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Curr Allergy Asthma Rep. 2004;4(2):123–31.

5. Panettieri R, Wang M, Braddock M, Bowen K, Colice G. Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program. Immunotherapy. 2018;10(6):473–90.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease;Clinical Pharmacology & Therapeutics;2024-01-24

2. Innovative Metrics for Reporting and Comparing the Glycan Structural Profile in Biotherapeutics;Molecules;2023-04-07

3. Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives;Frontiers in Immunology;2022-12-06

4. β‐Arrestin‐biased proteinase‐activated receptor‐2 antagonist C781 limits allergen‐induced airway hyperresponsiveness and inflammation;British Journal of Pharmacology;2022-12-05

5. Mechanistic modeling of a human IgG ₄ monoclonal antibody (tralokinumab) Fab‐arm exchange with endogenous IgG ₄ in healthy volunteers;CPT: Pharmacometrics & Systems Pharmacology;2022-01-12